A Phase 3 interventional study of Tirbanibulin and Vehicle ointment in Keratosis, Actinic, sponsored by Almirall, S.A.. Completed at 35 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by Almirall, S.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Keratosis, Actinic by Almirall, S.A. — none open to participants now, 1 under way, none of them phase 3. Keratosis, Actinic · Almirall, S.A..
Among the 14 studies in Keratosis, Actinic by Almirall, S.A., this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2023, is one of 7 in phase 3, and was the 14th registered.
343 studies on the registry are indexed under Keratosis, Actinic; 29 are open to participants now.
Browse Keratosis, Actinic studies →None of the 14 studies in Keratosis, Actinic by Almirall, S.A. is open now. The open studies under Keratosis, Actinic, anywhere →
Of the 21 Keratosis, Actinic studies recruiting now, 16 (76%) set no upper age limit and 1 (5%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 280 is above the median of 60 across 295 interventional studies indexed under Keratosis, Actinic.
Median enrollment 307 across the 12 interventional studies, 155 across the 2 observational. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
Almirall, S.A. is the lead sponsor of 66 studies on the registry; 9 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.
1 of the studies in Keratosis, Actinic by Almirall, S.A. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05387525Almirall, S.A.A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Keratosis, Actinic by Almirall, S.A., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy and safety of tirbanibulin 10 milligrams per gram (mg/g) ointment when applied to a treatment field (TF) larger than 25 square centimeters (cm\^2) and up to 100 cm\^2 in adult participants with actinic keratosis (AK).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will apply tirbanibulin 10 mg/g ointment once daily for 5 consecutive days beginning on Day 1. All participants will be evaluated for efficacy, safety, and tolerability at Day 8, 15, 29, and 57. Participants who do not achieve complete clearance (CC) at Day 57 will receive a second 5-day course of the treatment. Participants receiving a second treatment course will also be evaluated for efficacy, safety, and tolerability at Day 64, 71, and 85.
Drug: Tirbanibulin
Participants will apply vehicle ointment once daily for 5 consecutive days beginning on Day 1. All participants will be evaluated for efficacy, safety, and tolerability at Day 8, 15, 29, and 57. Participants who do not achieve CC at Day 57 will receive a second 5-day course of the treatment. Participants receiving a second treatment course will also be evaluated for efficacy, safety, and tolerability at Day 64, 71, and 85.
Other: Vehicle ointment
Participants will apply tirbanibulin ointment topically on the face or balding scalp with AK.
Also known as: Klisyri®
Participants will apply vehicle ointment topically on the face or balding scalp with AK.
Percent Change From Baseline in Lesion Count at Day 57
Percent change from baseline in the AK lesion count at Day 57 was reported.
Time frame: Baseline, Day 57
Percentage of Participants With Partial Clearance at Day 57
PC was defined as percentage of participants who achieved more than or equal to (\>=) 75 percent (%) clearance of AK lesions in the Treatment field (TF) on the face or scalp at Day 57.
Time frame: At Day 57
Percentage of Participants With Complete Clearance at Day 57
Complete clearance was defined as percentage of participants who achieved 100% clearance (no AK lesions) in the TF on the face or scalp at Day 57.
Time frame: At Day 57
Percentage of Participants With Partial Clearance at Day 113
Percentage of of participants with partial clearance at Day 113, defined as 100% clearance in the TF at Day 57 or, for participants receiving a second treatment course, ≥75% clearance at Day 113
Time frame: At Day 113
Percentage of Participants With Complete Clearance at Day 113
Percentage of participants with complete clearance by Day 113, defined as 100% clearance in the TF at Day 57 or, for participants receiving a second treatment course, 100% clearance at Day 113
Time frame: At Day 113
Local Tolerability Signs Composite Score at Specific Timepoints
Local Tolerability Signs Composite Score was assessed as the sum of six individual tolerability signs-erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. Each sign was graded on a scale from 0 (none) to 3 (severe) with a total score range of 0 to 18. The higher score indicates worst tolerability.
Time frame: At Day 1, 8, 15, 29, 57, 64, 71, 85, and 113
Maximum Local Tolerability Signs Composite Score in Treatment Course
Maximum local tolerability signs composite score was assessed as the sum of six individual tolerability signs-erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. Each sign was graded on a scale from 0 (none) to 3 (severe) with a total score range of 0 to 18. The higher score indicates worst tolerability.
Time frame: At Week 1 to 8 (Day 57) and Week 8 to 16 (Day 113)
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and TEAE of Special Interest
An AE is defined as any untoward medical occurrence in a clinical trial participant, regardless of the administration of the IMP and its causal relationship to it. unfavorable and unintended medical occurrence during the participant's participation in the trial, including deterioration of a pre-existing medical condition, an abnormal value in a laboratory assessment, or an abnormal finding in the physical examination. TEAE- AEs that occurred after the first administration of the IMP, either tirbanibulin or vehicle, during the study. An SAE is any untoward medical occurrence that at any dose resulted in death; is life threatening; required persistent/significant disability/incapacity; resulted in initial or prolonged in participant hospitalization; congenital anomaly/birth defect or otherwise considered medically important. AESIs included skin cancers \[including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma\] appearing within or outside the TF during the study.
Time frame: From Baseline up to Day 113
| Milestone | Vehicle Ointment | Tirbanibulin 10 mg/g |
|---|---|---|
| Started | 93 | 187 |
| Safety population | 93 | 186 |
| Completed | 74 | 165 |
| Not completed | 19 | 22 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 0 | 3 |
| Withdrew: Protocol deviation | 0 | 1 |
| Withdrew: Withdrawal by subject | 18 | 16 |
Percent change from baseline in the AK lesion count at Day 57 was reported.
| Percent change | Vehicle Ointment | Tirbanibulin 10 mg/g |
|---|---|---|
| Percent Change From Baseline in Lesion Count at Day 57 | -25.23 ± 3.96 | -64.15 ± 2.87 |
PC was defined as percentage of participants who achieved more than or equal to (\>=) 75 percent (%) clearance of AK lesions in the Treatment field (TF) on the face or scalp at Day 57.
| Percentage of participants | Vehicle Ointment | Tirbanibulin 10 mg/g |
|---|---|---|
| Percentage of Participants With Partial Clearance at Day 57 | 20.4 (13.49 to 29.72) | 58.8 (51.66 to 65.63) |
Complete clearance was defined as percentage of participants who achieved 100% clearance (no AK lesions) in the TF on the face or scalp at Day 57.
| Percentage of participants | Vehicle Ointment | Tirbanibulin 10 mg/g |
|---|---|---|
| Percentage of Participants With Complete Clearance at Day 57 | 15.1 (9.18 to 23.70) | 41.2 (34.37 to 48.34) |
Percentage of of participants with partial clearance at Day 113, defined as 100% clearance in the TF at Day 57 or, for participants receiving a second treatment course, ≥75% clearance at Day 113
| Percentage of participants | Vehicle Ointment | Tirbanibulin 10 mg/g |
|---|---|---|
| Percentage of Participants With Partial Clearance at Day 113 | 25.8 (18.00 to 35.53) | 65.2 (58.17 to 71.70) |
Percentage of participants with complete clearance by Day 113, defined as 100% clearance in the TF at Day 57 or, for participants receiving a second treatment course, 100% clearance at Day 113
| Percentage of participants | Vehicle Ointment | Tirbanibulin 10 mg/g |
|---|---|---|
| Percentage of Participants With Complete Clearance at Day 113 | 23.7 (16.17 to 33.23) | 56.1 (48.98 to 63.07) |
Local Tolerability Signs Composite Score was assessed as the sum of six individual tolerability signs-erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. Each sign was graded on a scale from 0 (none) to 3 (severe) with a total score range of 0 to 18. The higher score indicates worst tolerability.
| Score on a scale | Vehicle Ointment | Tirbanibulin 10 mg/g |
|---|---|---|
| Baseline (Day 1) | 0.8 ± 1.68 | 0.9 ± 1.64 |
| At Day 8 | 1.0 ± 1.47 | 4.0 ± 2.72 |
| At Day 15 | 0.7 ± 1.26 | 1.8 ± 1.72 |
| At Day 29 | 0.6 ± 1.23 | 0.6 ± 0.99 |
| At Day 57 | 0.5 ± 1.21 | 0.4 ± 0.84 |
| At Day 113 | 0.3 ± 0.84 | 0.2 ± 0.75 |
Maximum local tolerability signs composite score was assessed as the sum of six individual tolerability signs-erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. Each sign was graded on a scale from 0 (none) to 3 (severe) with a total score range of 0 to 18. The higher score indicates worst tolerability.
| Score on a scale | Vehicle Ointment | Tirbanibulin 10 mg/g |
|---|---|---|
| At Week 1 to 8 | 1.3 ± 1.80 | 4.1 ± 2.68 |
| At Week 8 to 16 | 0.7 ± 0.93 | 2.9 ± 2.12 |
An AE is defined as any untoward medical occurrence in a clinical trial participant, regardless of the administration of the IMP and its causal relationship to it. unfavorable and unintended medical occurrence during the participant's participation in the trial, including deterioration of a pre-existing medical condition, an abnormal value in a laboratory assessment, or an abnormal finding in the physical examination. TEAE- AEs that occurred after the first administration of the IMP, either tirbanibulin or vehicle, during the study. An SAE is any untoward medical occurrence that at any dose resulted in death; is life threatening; required persistent/significant disability/incapacity; resulted in initial or prolonged in participant hospitalization; congenital anomaly/birth defect or otherwise considered medically important. AESIs included skin cancers \[including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma\] appearing within or outside the TF during the study.
| Participants | Vehicle Ointment | Tirbanibulin 10 mg/g |
|---|---|---|
| TEAEs | 28 | 79 |
| Serious TEAEs | 2 | 9 |
| TEAE of Special Interest | 2 | 2 |
Collected over Baseline up to Day 113. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vehicle Ointment | 0/93 (0%) | 2/93 (2.2%) | 28/93 (30.1%) |
| Tirbanibulin 10 mg/g | 1/186 (0.5%) | 9/186 (4.8%) | 79/186 (42.5%) |
| Event | Vehicle Ointment | Tirbanibulin 10 mg/g |
|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/93 | 2/186 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/93 | 0/186 |
| Renal colicRenal and urinary disorders | 1/93 | 0/186 |
| Renal failureRenal and urinary disorders | 1/93 | 0/186 |
| MelaenaGastrointestinal disorders | 0/93 | 1/186 |
| Peritoneal adhesionsGastrointestinal disorders | 0/93 | 1/186 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/93 | 1/186 |
| PneumoniaInfections and infestations | 0/93 | 1/186 |
| Clavicle fractureInjury, poisoning and procedural complications | 0/93 | 1/186 |
| Hepatic cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/93 | 1/186 |
| Event | Vehicle Ointment | Tirbanibulin 10 mg/g |
|---|---|---|
| ErythemaSkin and subcutaneous tissue disorders | 0/93 | 27/186 |
| Skin exfoliationSkin and subcutaneous tissue disorders | 0/93 | 8/186 |
| Administration site exfoliationGeneral disorders | 0/93 | 6/186 |
| PruritusSkin and subcutaneous tissue disorders | 2/93 | 6/186 |
| Skin burning sensationSkin and subcutaneous tissue disorders | 0/93 | 6/186 |
| HypertensionVascular disorders | 3/93 | 0/186 |
| Actinic keratosisSkin and subcutaneous tissue disorders | 2/93 | 5/186 |
| Application site pruritusGeneral disorders | 0/93 | 4/186 |
| Application site exfoliationGeneral disorders | 0/93 | 4/186 |
| NasopharyngitisInfections and infestations | 2/93 | 4/186 |
Intention-To-Treat (ITT) population included all randomized participants.
| Age, Continuous(years) | Vehicle Ointment | Tirbanibulin 10 mg/g | Total |
|---|---|---|---|
| Mean | 73.1 ± 9.34 | 73.5 ± 9.01 | 73.4 ± 9.11 |
| Sex: Female, Male(Participants) | Vehicle Ointment | Tirbanibulin 10 mg/g | Total |
|---|---|---|---|
| Female | 17 | 28 | 45 |
| Male | 76 | 159 | 235 |
| Ethnicity (NIH/OMB)(Participants) | Vehicle Ointment | Tirbanibulin 10 mg/g | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 13 | 23 |
| Not Hispanic or Latino | 82 | 166 | 248 |
| Unknown or Not Reported | 1 | 8 | 9 |
| Race (NIH/OMB)(Participants) | Vehicle Ointment | Tirbanibulin 10 mg/g | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 68 | 136 | 204 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 25 | 51 | 76 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2023 to primary completion in Apr 2025, 16 months.
Results were first posted in Jun 2026, 1 year 2 months after primary completion.
Of 26 phase 3 interventional studies under Keratosis, Actinic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 22. This study's 16 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirbanibulin